Señales en vivo de 083790.KQ | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (1 jul 2024 @ 01:54):
Our systems believe the stock currently is overvalued by -0.16% compare to its pairs and should correct downwards.

Stats
Volumen de hoy	110 142
Volumen promedio	199 147
Capitalización de mercado	208.20B
EPS	KRW-98.15 ( Q1 \| 2024-03-31 )
Próxima fecha de ganancias	( KRW0 ) 2024-08-14
Last Dividend	KRW0 ( N/A )
Next Dividend	KRW0 ( N/A )
P/E	0 (Sector) 0 (Industry) 0
ATR14	KRW4.43 (0.16%)

Correlación (AI algo v.1.1b): Overvalued: -0.16% KRW2 804.40 paired level. (El Algoritmo Rastrea Los Cambios De Las Acciones Más Correlacionadas En Tiempo Real Y Proporciona Una Actualización Instantánea)

Volumen Correlación

Largo: -0.10 (neutral)

Corto: 0.34 (neutral)

Signal:(63.762) Neutral

CrystalGenomics, Inc. Correlación

10 Correlaciones Más Positivas

10 Correlaciones Más Negativas

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

CrystalGenomics, Inc. Correlación - Moneda/Commodity

-0.65
( moderate negative )

-0.27
( neutral )

-0.60
( weak negative )

-0.45
( neutral )

0.12
( neutral )

0.63
( weak )

CrystalGenomics, Inc. Finanzas

Annual	2023
Ingresos:	KRW4.88B
Beneficio Bruto:	KRW1.46B (29.86 %)
EPS:	KRW-665.90

FY	2023
Ingresos:	KRW4.88B
Beneficio Bruto:	KRW1.46B (29.86 %)
EPS:	KRW-665.90

FY	2023
Ingresos:	KRW17.46B
Beneficio Bruto:	KRW9.07B (51.96 %)
EPS:	KRW132.36

FY	2022
Ingresos:	KRW16.25B
Beneficio Bruto:	KRW8.47B (52.13 %)
EPS:	KRW117.19

Financial Reports:

No articles found.

CrystalGenomics, Inc. Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

CrystalGenomics, Inc.

CrystalGenomics, Inc., a biopharmaceutical company, discovers and develops structural chemoproteiomics-based drugs in Korea. Its lead development candidate is NSAID (CG100649), which is a tissue specific anti-inflammatory agent with cardiovascular, gastrointestinal, and renal safety profiles that has completed Phase IIa clinical trial. The company's drug candidates also include CG200745, a histone deacetylase inhibitor for cancer, which is in Phase I clinical trial; and CG400549, an antibiotic candidate for methicillin resistant staphylococcus aureus and vancomycin resistant staphylococcus aureus, which is in Phase I clinical trial. In addition, it offers cloning, expression, purification, and characterization of proteins of interest; and assay and structure services. The company has drug discovery collaborations with AstraZeneca, Daiichi-Sankyo, SBI-Biotech, Carna Biosciences, Yuyu Pharma, AmorePacific, Hanmi Pharmaceuticals, and ProQuest Investments. CrystalGenomics, Inc. was founded in 2000 and is headquartered in Seongnam, South Korea.